Xencor (NASDAQ:XNCR) Sees Large Volume Increase – Should You Buy?

Xencor, Inc. (NASDAQ:XNCR) shares saw strong trading volume on Monday . 425,273 shares were traded during mid-day trading, a decline of 52% from the previous session’s volume of 895,292 shares.The stock last traded at $26.1560 and had previously closed at $26.06.

Wall Street Analysts Forecast Growth

XNCR has been the subject of a number of analyst reports. Zacks Research raised Xencor from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Cantor Fitzgerald lifted their price target on shares of Xencor from $43.00 to $44.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Wedbush boosted their price target on shares of Xencor from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Truist Financial reduced their price objective on shares of Xencor from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a research report on Monday, May 11th. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $24.86.

Xencor Stock Performance

The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of -12.22 and a beta of 0.85. The stock’s 50-day moving average price is $19.80 and its 200-day moving average price is $14.79.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.51. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.The business had revenue of $51.22 million during the quarter, compared to the consensus estimate of $18.89 million. During the same quarter in the previous year, the company posted ($0.41) EPS. The business’s revenue was up 17.4% on a year-over-year basis. Analysts anticipate that Xencor, Inc. will post -3 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of XNCR. AQR Capital Management LLC purchased a new stake in Xencor in the 1st quarter valued at approximately $438,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Xencor by 9.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company’s stock worth $471,000 after acquiring an additional 3,692 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Xencor by 89.9% in the first quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company’s stock valued at $7,732,000 after acquiring an additional 344,088 shares in the last quarter. Creative Planning boosted its stake in shares of Xencor by 25.3% during the second quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 3,661 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in Xencor by 170.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 330,007 shares of the biopharmaceutical company’s stock worth $2,594,000 after purchasing an additional 208,182 shares in the last quarter.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.